Biologic Therapies Receive FDA Clearance for Drillable Bone Marrow Cannulas

The United States Food and Drug Administration has cleared Bio-MAC and Bio-CORE cannulas - products for regenerative medicine developed by a medical device firm called Biologic Therapies in Florida. The Bio-MAC Bone Marrow Aspiration Cannula and Bio-CORE Bone Marrow Biopsy Cannula are minimally invasive devices that are inserted into bone with any standard surgical drill. The aim of both the devices is to reduce fracturing to bone around the site of insertion and also reduce discomfort that the patient may feel during the procedure.

“Our products enable physicians to aspirate bone marrow in their own office with only local anesthesia, which is revolutionary,” said Dr. Wade McKenna, Biologic Therapies’ Chief Medical Director.

The devices are available in a variety of lengths, allowing fast and easy bone marrow draws throughout the skeletal anatomy, including the tibia, humerus and calcaneus bones.

“The ability to aspirate a patient’s marrow, concentrate the marrow in a centrifuge to derive the maximum number of regenerative cells and growth factors, and then give the concentrated cells and growth factors back to the patient in a physician’s office makes regenerative cell therapy a much easier, more available and less costly procedure. The entire point-of-care procedure takes less than 30 minutes. Of course, the Bio-MAC and Bio-CORE are also used in hospitals and surgery centers, said McKenna. 

Source-Medindia